Proteomic Analysis of Pre-Invasive Serous Lesions of the Endometrium and Fallopian Tube Reveals Their Metastatic Potential

Mitchell Acland¹, Georgia Arentz¹, Max Mussared², Fergus Whitehead³, Peter Hoffmann⁴*, Manuela Klingler-Hoffmann⁴* and Martin K. Oehler⁴,⁵,⁶*

¹ Adelaide Proteomics Centre, School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia, ² School of Mathematical Sciences, The University of Adelaide, Adelaide, SA, Australia, ³ Cytopathology Department, Clinpath Pathology, Adelaide, SA, Australia, ⁴ Future Industries Institute, Mawson Lakes Campus, University of South Australia, Adelaide, SA, Australia, ⁵ Department of Gynaecological Oncology, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia, ⁶ Robinson Research Institute, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, The University of Adelaide, SA, Australia

Serous endometrial cancer (SEC) and high grade serous ovarian cancer (HGSOC) are aggressive gynecological malignancies with high rates of metastasis and poor prognosis. Endometrial intraepithelial carcinoma (EIC), the precursor for SEC, and serous tubal intraepithelial carcinoma (STIC), believed to be the precursor lesion for HGSOC, can also be associated with intraabdominal spread. To provide insight into the etiology of these precancerous lesions and to explore the potential molecular mechanisms underlying their metastatic behavior, we performed a proteomic mass spectrometry analysis in a patient with synchronous EIC and STIC. Through histological and molecular identification of precancerous lesions and adjacent healthy tissue. The proteomic analysis of STIC and EIC showed remarkable overlap in the proteomic patterns, reflecting early neoplastic changes in proliferation, loss of polarity and attachment. Our proteomic analysis showed that both EIC and STIC, despite being regarded as premalignant lesions, have metastatic potential, which correlates with the common presentation of invasive serous gynecological malignancies at advanced stage.

Keywords: proteomics, serous tubal intraepithelial carcinoma, endometrial intraepithelial carcinoma, serous endometrial carcinoma, high grade serous ovarian carcinoma

INTRODUCTION

Endometrial cancer (EC) is the 6th most common cancer in women worldwide and is the most common gynecological malignancy (1). Despite significant advances in early detection (2), molecular subtyping (3, 4), and new or improved treatment regimens (5), the relative survival of patients with EC has declined in recent times (6, 7).
Serous endometrial carcinoma (SEC) is a highly aggressive malignancy (8). It represents only 10% of EC cases (9, 10) but is responsible for 39% of EC related deaths (11) and is frequently diagnosed at late stage when prognosis is poor (9, 10). The current model of SEC development suggests that it evolves from a pre-neoplastic lesion in atrophic endometrium called endometrial glandular dysplasia (EmGD) (12, 13). This lesion then progresses further into endometrial intraepithelial carcinoma (EIC) and, finally, into SEC (14).

EmGD is characterized by loss of cell polarity, nuclear atypia, and nuclear hyperchromasia (12). It has a marked loss of heterozygosity in TP53 and chromosome p1; however, this is to a lesser extent than that seen in EIC and SEC (12). Although quite difficult to identify, nucleomegaly and staining for p53, MIB-1 as well as IMP3 are characteristics of EmGD (14). The connection between EmGD and SEC has been confirmed through identical mutations observed in EmGD and subsequent SEC (15).

EIC was first described in the 1990s (16) and seen to arise almost exclusively in atrophic endometrium and in the context of SEC in a majority of cases (17). EIC exhibit similar features as EmGD but with further nucleomegaly, nuclear irregularity and hyperchromasia (14). However, cases of EIC associated with extraterine metastasis suggest that EIC may more closely resemble SEC (18, 19). This early peritoneal spread is in stark contrast to non-serous endometrial cancers which usually do not show early peritoneal spread but preferentially invade the myometrium and spread to the lymph nodes (18, 19).

SEC closely resembles other serous cancers of the female genital tract, such as high grade serous ovarian cancer (HGSOC) (4). Both diseases share similar molecular features and clinical properties (20) and, consequently, are treated in a similar way (21, 22).

In recent years the fallopian tube has been identified as the precursor site of HGSOC, specifically serous tubal intraepithelial carcinoma (STIC) (23–27). These lesions are identified histopathologically by a “p53 signature” comprised of strong p53 staining (28), p53 mutations (29), positive γ-H2AX staining (indicating DNA damage) and lack of Ki-67 staining (indicating low proliferation) (30) (Table 1). STICs share many genomic features with HGSOC, such as genomic instability (31, 32), and HGSOC has a gene expression profile more similar to the fallopian epithelium than the ovarian surface epithelium (33).

Results from studies using mouse models have established a connection between STIC and subsequent HGSOC (34, 35). Inactivation of PTEN, p53 and BRCA1/2 in the fallopian tubes of mice resulted in STIC and concurrent HGSOC with ovarian and peritoneal spread (34, 35). However, in the absence of BRCA1/2 inactivation, STIC developed but did not progress to metastatic HGSOC in this mouse model (34).

Cases of HGSOC arising in the absence of STIC (35–37) have also been reported suggesting that other, as yet unidentified, precursor lesions might exist (38). “Early Serous Tubal Proliferations” (ESTP) have been identified as a potential HGSOC precursor. They are found in the fimbria (30), demonstrate DNA damage (30), and are found in non-ciliated cells, which also give rise to STIC (39). A physical and lineage continuity has been demonstrated between ESTP and STIC suggesting that some ESTP give rise to STIC and subsequently to HGSOC (30, 32).

The understanding that HGSOC arises from the fallopian tube in many cases has changed the understanding of serous ovarian cancer. Now serous cancers of the fallopian tube, peritoneum and ovary are thought to share a common origin in the fallopian tube (20). While it is well established that many HGSOC arise from the fallopian tube, it has not been excluded that some serous cancers of the endometrium and ovary may share common origins. For example, Roelofsen et al. (40) suggested that some serous ovarian cancers (SOC) may arise from EIC by showing that they shared TP53 mutations, similar expression of p53, Ki67, estrogen, and progesterone receptors (40). Additionally, Tolcher et al. (20) analyzed 38 patients with SEC and investigated their fallopian tubes. They found STIC, without evidence of tubal metastasis, in 2 of these cases (20).

To better understand the potential link between serous preinvasive lesions of the female genital tract and serous gynaecological cancer, molecular investigations of the precursor lesions of the endometrium and fallopian tube are required. Here, we present the first proteomic analysis of synchronous precancerous lesions of the endometrium and fallopian tubes in a patient without invasive malignancy, by means of mass spectrometry. This precludes the possibility of these premalignant lesions representing metastases from established primary tumors. The analysis of EIC and STIC in this context provides insight into the temporal and mechanistic features of their development and dissemination.

**MATERIALS AND METHODS**

**Sample**

Archived formalin-fixed paraffin-embedded (FFPE) fallopian tube and endometrial tissues from a 67-year-old female who

---

**TABLE 1 | Morphological and molecular features of precancerous lesions of the gynecological tract.**

| Location       | Precancerous lesion | Morphological features | Molecular features                                                                 |
|----------------|---------------------|------------------------|-----------------------------------------------------------------------------------|
| Endometrium    | EmGD                | Some nuclear atypia, some nucleomegaly. | Low rates of loss of heterozygosity in TP53 and chromosome P1; p53 mutations in 50% of cells. Staining for P53, MIB1, and IMP3. |
|                | EIC                 | Extensive nuclear atypia, extensive nucleomegaly, hyperchromasia. | High rates of loss of heterozygosity in TP53 and chromosome P1; p53 mutations in 75% of cells. Strong staining for P53, MIB1, and IMP3. |
| Fallopian tube | ESTP                | No visible morphological features. | TP53 mutations, p53 staining, DNA damage.                                      |
|                | STIC                | Hyperchromasia, nucleomegaly. | TP53 mutations, p53 and MIB1 staining, DNA damage, Chromosomal instability. |
had undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometrial hyperplasia was retrieved for analysis with approval of the Research Ethics Committee of the Royal Adelaide Hospital. The fallopian tube and endometrial tissues were processed using standard procedures, stained with hematoxylin and eosin, and annotated by a pathologist. P53 and MIB1 immunostaining was also performed to confirm the location of precancerous lesions.

**Laser Microdissection and Sample Preparation**

FFPE tissues were sectioned at 4-µm thickness, water bath mounted onto PEN membrane slides (Micro-Dissect, Herborn, Germany), and deparaaffinized by submersion in xylene for 5 min, following by two 2-min incubations in 100% ethanol, and two 5-min incubations in water. Areas of STIC, EIC and adjacent healthy epithelium were dissected using a Leica AS LCM microscope (Leica Microsystems, Wetzlar, Germany) into 20 µl of 10 mM citric acid buffer (pH = 6) and subjected to heat induced antigen retrieval by incubation at 100°C for 90 min. The solution containing the protein extracts were digested with trypsin gold (Promega, Madison, WI, USA) as described in Mittal et al. (41) using a modified FASP method (42). In brief, protein extracts were mixed with 0.2 ml of 8M urea in 0.1M Tris/HCl, pH 8.5 before being loaded into a 30k Microcon filtration device (Millipore) and centrifuged at 14,000g for 15 min. This step was repeated to ensure the removal of any residual contaminants. Samples were reduced with 5 mM DTT (Roche) for 45 min at room temperature and alkylated with 10mM iodoacetamide (IAA) (GE Healthcare, Little Chalfont, UK) for 30 min at room temperature in the dark followed by centrifugation at 14,000g for 15 min. The protein concentrate was diluted with 0.2mL of 8M urea in 0.1M Tris/HCl, pH 8.5, and spun again at 14,000g for 15 min. This step was repeated twice. Samples were buffer with 10mM NH4HCO3 and digested with 100ng trypsin gold overnight at 37°C. Peptides were collected by centrifugation of the filter unit at 14,000g for 20 min.

**NanoFlow Liquid Chromatography Tandem Mass Spectrometry**

NanoFlow liquid chromatography tandem mass spectrometry (Nano-LC-MS/MS) was performed on each sample in duplicate using an Ultimate 3000 RSLC system (Thermo-Fisher Scientific, Waltham, USA) coupled to an Impact HD™ QTOF mass spectrometer (Bruker Daltonics, Bremen, Germany) via an Advance CaptiveSpray source (Bruker Daltonics). Peptide samples were pre-concentrated onto a C18 trapping column (Acclaim PepMap100 C18 75 µm x 20 mm, Thermo-Fisher Scientific) at a flow rate of 5 µl/min in 2% (v/v) ACN 0.1% (v/v) TFA for 10 min. Peptide separation was performed using a 75 µm ID C18 column (Acclaim PepMap100 C18 75 µm x 50 cm, Thermo-Fisher Scientific) at a flow rate of 0.2 µl/min using a linear gradient from 5 to 45% B (A: 5% (v/v) ACN 0.1% (v/v) FA, B: 80% (v/v) ACN 0.1% (v/v) FA) over 130 min, followed by a 20-min wash with 90% B, and a 20-min equilibration with 5% A. MS scans were acquired in the mass range of 300 to 2,200 m/z in a data-dependent fashion using Bruker’s ShotGun Instant Expertise™ method. This method uses IDAS (intensity dependent acquisition speed) to adapt the speed of acquisition depending on the intensity of precursor ions (fixed cycle time), and RT² (RealTime Re-Think) to exclude previously selected precursor ions from undergoing re-fragmentation unless the chromatographic peak intensity of the ion has increased by a factor of 5. Singly charged precursor ions were excluded from acquisition. Collision energy ranged from 23% to 65% as determined by the m/z of the precursor ion.

**Data Analysis**

Spectra were analyzed using the MaxQuant software (version 1.5.2.8) with the Andromeda search engine (43) against the UniProt non-redundant human database. The standard Bruker QTOF settings in MaxQuant were used with a mass error tolerance of 40 ppm. The variable modifications of oxidation of methionine and the fixed modification of carbamidomethyl of cysteines were specified, with the digestion enzyme specified as trypsin. The protein false discovery rate (FDR) and peptide spectrum match FDRs were both set to 1% using a target decoy approach, with a minimum peptide length of 7 amino acids (43). Only unique and razor peptides were used when reporting protein identifications.

**Gene Expression Analysis**

In order to assess the gene expression levels of the corresponding proteins of interest in early stage I ovarian carcinoma tissues, the dataset of Yoshihara et al. (44) [Gene Expression Omnibus (GEO) Accession GSE12470, http://www.ncbi.nlm.nih.gov/geo/] was considered. From this dataset the expression of EPCAM and CAPS was considered in 8 in early stage I patients compared to 10 healthy peritoneum control tissues. The results were measured as log transformed and compared using paired T-tests and p-values < 0.05 were considered significant. Full patient details are available in the Yoshihara et al. (44) manuscript.

To assess the gene expression levels of the corresponding proteins of interest in early stage 1 endometrial carcinoma tissue, R was used to investigate the data set of Days et al. (46) (GEO Accession GDS4589, http://www.ncbi.nlm.nih.gov/geo/). This this dataset the expression of EPCAM and CAPS were investigated in 79 endometrioid and 12 serous papillary endometrial carcinoma tissues, and in 12 normal control tissues. The results were natural log transformed and compared using paired T-tests. P-values < 0.05 were considered significant. Full patient details are available through the Day’s et al. (46) manuscript.
To evaluate the gene expression levels of corresponding proteins in different subtypes of endometrial carcinoma tissue, R was used to investigate the data set of Kandolth et al. (4) (https://gdc.cancer.gov/node/875). From this data set the expression of TPP3, SPATA18, ERO1A, SORD and VCAN were investigated in 13 CN high, 15 CN low, 16 MSI hypermutated, and 4 POLE ultra-mutated carcinoma tissues. Transformation of the data set is detailed in Kandolth et al. (4). Groups were compared using paired T-tests and p-values < 0.05 were considered significant. Full patient details are available in the Kandolth et al. (4) manuscript.

RESULTS
Histological Analysis Identifying STIC and EIC
Upon analysis of the H&E stained tissue sections, atypical intraepithelial proliferation involving a small population of cells in the endometrium were identified. These changes were consistent with early stages of EIC (Table 1). Similarly, atypical changes involving a small population of cells in the fimbriated tube (Table 1), consistent with early stages of STIC, were detected and both EIC and STIC are represented in Figure 1. Immunoperoxidase staining for p53 and MIB1 revealed atypical intraepithelial epithelial proliferations in both the fimbriated tube and endometrial lining, confirming the presence of STIC and EIC (data not shown).

Proteomic Comparison of Healthy Epithelia to STIC and EIC
Regions of STIC, EIC, and adjacent healthy epithelium were laser microdissected (LMD) from sectioned tubal and endometrial specimens and analyzed by Nano-LC-MS/MS. In total, 453 proteins were detected across the 4 tissue types (369 proteins in the STIC, 110 proteins in healthy tubal epithelium, 428 proteins in EIC, and 162 proteins in healthy endometrial epithelium (Supplementary Table 1).

When comparing the numbers of identified proteins, the greatest overlap occurred between STIC and EIC with 348 identical proteins identified in both samples. Across all tissue types 73 proteins were detectable, with 96 identical proteins identified in both the STIC and healthy tubal tissue, 157 identical proteins detected in both the EIC and healthy endometrial tissue, and 85 identical proteins were detected in both healthy tissues (Figure 2).

Proteins Relevant to STIC, EIC, and the Development of Gynecological Cancer
In analyzing potential links between STIC and EIC cells and their respective invasive carcinomas, two of the identified proteins were of particular interest based on their involvement in gynecological cancer development: Epithelial cell adhesion molecule (EPCAM) and Calcyphosin (CAPS) (47–49). EPCAM was identified in both the STIC and EIC tissue samples but was not detected in either of the healthy tissues while CAPS was only detected in the healthy tube and in STIC.

FIGURE 1 | Hematoxylin and Eosin stained fallopian tube (A, B) and endometrium tissue (C, D) at 6× (A, C) and 12× (B, D) magnification. Areas of STIC (B) and EIC (D) are indicated by the red arrows.
Expression of EPCAM and CAPS in Early Stage Serous Ovarian Carcinomas Compared to Healthy Peritoneal Tissue

To evaluate the expression of EPCAM and CAPS in early stage I serous ovarian carcinoma tissues, oligonucleotide microarray data was considered from the GEO data set GSE12470 (44). We chose to investigate the expression of these genes in early stage ovarian cancer as this is expected to be the stage following STIC in the development of serous ovarian cancer. STIC lesions were not deemed an appropriate comparison samples as they are often taken in the context of metastatic disease and potentially represent metastatic implants, and therefore more developed cancer, rather than true precursor lesions.

The gene expression levels were analyzed in 10 healthy peritoneal control tissues compared to 8 Stage I serous EOC tissues. The median expression levels of both CAPS and EPCAM were found to be significantly increased in the Stage I serous OC tissues compared to healthy peritoneal controls (p = 0.00014 and p = 3.3 × 10^{-77}, respectively) (Figure 3).

Healthy OSE is infrequently available for research purposes given healthy ovaries are rarely removed during any type of medical procedure. Healthy peritoneum is an effective control because the lining of the ovaries is comprised of a single-cell mesothelial layer of poorly differentiated epithelium derived from the coelomic epithelium and extended to the serosa peritoneal cavity (50). In addition, it has been reported that peritoneal mesothelium and OSE are structurally very similar (51) and are both negative for EPCAM and CAPS expression (52, 53).

Expression of EPCAM and CAPS in Early Stage Endometrial Carcinoma Compared to Healthy Endometrial Tissue

To assess the expression of EPCAM and CAPS in early stage endometrial cancer, oligonucleotide microarray data was considered from the GEO data set GDS4589. The gene expression levels were analyzed from 79 endometrioid and 12 serous papillary endometrial carcinomas as well as 12 healthy controls. The median expression of CAPS was increased significantly in EEC (p = 0.00066), while it was significantly decreased in SEC (p = 0.023) compared to healthy endometrium. The median expression of EPCAM was significantly increased in EEC (p = 0.02) and further increased in SEC (p = 0.0007) compared to healthy controls (Figure 4).

Expression of Proteins Identified Exclusively in the STIC or EIC Across Ovarian Cancer Subtypes

Proteins detected exclusively in either the STIC or EIC tissues were analyzed to determine if their expression is specific to...
certain gynecological tissues. Marker proteins expressed exclusively by the precancerous cells of either the tube or endometrium, which are also expressed by ovarian carcinomas, may aid in determining the tissue specific origin of HGSOC. Eighteen proteins were detected exclusively in the STIC tissue and 57 proteins in the EIC tissue. Of these proteins a small number appear to be specific to certain gynecological tissues according to Protein Atlas; 2 identified from STIC (MIEAP, TPPP3), and 3 identified from EIC (ERO1A, DHSO, CSPG2/VCAN). These proteins and their tissue specificities across all gynecological tissues are listed in Table 2. The remaining proteins appeared to be more homogenously expressed and hence were not analyzed further.

The gene expression levels corresponding to the proteins listed in Table 2 were compared using oligonucleotide microarray data from the GEO data set GSE6008 (Figure 5).
For the gene *TPPP3* there was reduced expression in ovarian clear cell carcinoma compared to healthy tissue and other ovarian cancer subtypes. *SORD* showed significantly lower expression levels in the normal control tissues, and to a smaller extent, in serous ovarian carcinoma compared to the other subtypes. The high expression of *SORD*, whose related protein was detected only in EIC in our data set, in non-SOC was unexpected as the protein atlas reports low expression of *SORD* in ovarian cancer. CSPG2/VCAN expression, which was detected at the protein level in EIC only, was increased in CCOC when
compared to the normal tissue and other EOC subtypes (Figure 5).

Expression of Proteins Identified Exclusively in STIC or EIC Across Endometrial Cancer Subtypes

By investigating the gene expression corresponding to proteins in our data set which are enriched in specific gynecological tissues, we aimed to investigate the connection between preneoplastic lesions of the endometrium and tube with subtypes of endometrial cancer as defined by the TCGA. The expression levels of the genes corresponding to the proteins listed in Table 1 were compared using oligonucleotide microarray data from Kandolth et al. (4) (https://gdc.cancer.gov/node/875) (Figure 6).

They were selected as their related proteins were found exclusively in a precancerous lesion and their abundance

FIGURE 6 | Expression levels of genes whose proteins are associated with specific gynecological tissues. (A) ERO1A, (B) TPPP3, (C) SPATA18, (D) SORD, and (E) VCAN in 13 copy number (CN) high, 16 micro satellite instability (MSI) hypermutated, 4 POLE ultra-mutated, and 15 CN low. Here, the blue dots represent data points from late stage patients while the red represent early stage cancers. Data from Kandolth et al. (4) (https://gdc.cancer.gov/node/875).
(according to protein atlas) was unique to specific gynecological tissue. However, most did not show different gene expression between the TCGA defined subtypes, except for TPPP3 and SPATA18, which both showed decreased expression in the CN high (serous) subgroup compared to other subtypes (Figure 6). These proteins were detected exclusively in STIC in our analysis and their expression was seen to be decreased in SEC compared to healthy controls (Supplementary Figure 2).

Proteins Associated With Metastasis Identified in STIC or EIC

The 34 identified proteins expressed exclusively in STIC and/or EIC which are known to be involved in metastasis or migration were listed in Supplementary Table 2. Most of these proteins are implicated in the promotion of metastasis, with the exceptions of Galectin-9 (54, 55), Mimecan (56, 57), and Catenin alpha-1 (58, 59) which have been implicated in the inhibition of metastasis.

DISCUSSION

The application of proteomic techniques, particularly that of mass spectrometry, hold the potential to provide a temporal snapshot of the molecular features within a given sample. Here, we provide what is, to the best of our knowledge, the first proteomic analyses of synchronous precursor lesions of serous endometrial and high-grade ovarian cancer. Through histological and molecular identification of precancerous lesions, followed by laser-capture microdissection and mass spectrometry analysis, we were able to identify over 450 proteins within the precancerous lesions and adjacent healthy tissue. The proteomic profiles of the precancerous lesions showed striking similarity (Figure 1) and shared a molecular profile indicative of metastatic transformation (Supplementary Table 2). To investigate the connection between these precancerous lesions and serous gynecological malignancies we investigated the gene expression of several proteins of interest in serous endometrial and ovarian cancer data sets (Figures 3-6).

EPCAM and CAPS were selected for further investigation based on their implication in the development of ovarian and endometrial cancer (47-49). Genomic analysis of their expression in Stage I SOC compared to peritoneal control tissue revealed significantly increased levels in the cancerous specimens (Figure 3). It is well recognized that EPCAM expression has a complex relationship to SOC development (60); however, it has not previously been identified in STIC or other gynecological precancerous lesions. This transmembrane adhesion molecule plays a role in migration and proliferation in wound healing (61) as well as the maintenance of pluripotency in stem cells (62).

The exact function of CAPS is unknown, but it is a suggested target of cAMP-dependent protein kinase and has been implicated in the cAMP and calcium-phosphatidylinositol signaling cascades (63). According to protein atlas, CAPS has high expression in the fallopian tube but is not expressed in healthy OSE (http://www.proteinatlas.org/ENSG00000152611-CAPS/tissue) which is in agreement with our identification of this protein in both the healthy fallopian tissue and STIC. Interestingly, CAPS gene expression was seen to be increased in SOC compared to control tissue (Figure 3). Furthermore, EPCAM is not expressed in healthy ovarian surface epithelium (OSE) (53) but is frequently up regulated in ovarian cancer (60). The single case study presented here is insufficient to draw broader conclusions about potential markers of tissues of origin, but we believe that expression of EPCAM and CAPS merit further investigation in a larger cohort.

To further investigate proteins which may act as markers of tissue of origin in SEC or SOC, we investigated proteins identified exclusively in either the STIC or EIC which were unique to specific gynecological tissues according to protein atlas. CSGP/VCAN was identified exclusively in EIC, was seen to have increased expression in COCC compared to other ovarian cancer cell types (Figure 5) and had increased expression in SEC compared to healthy control tissue (Supplementary Figure 2). This protein has been previously seen to be increased in COCC (64, 65) and represents a potential link between EIC and COCC. COCC has been suggested to arise from endometriosis lesions (66) potentially representing a pathway for endometrial origin of COCC.

A previous mass spectrometry-based analysis of ovarian cancer precursor lesions was performed by Levenon et al. (67) and investigated ex vivo culture derived cells from fallopian tube fimbria (67). Their proteomic analysis identified 11 different ovarian cancer biomarkers present in this ex vivo model. A larger study by M. Eckart et al. (68) investigated both tumor and stroma tissue from STIC, invasive fallopian tube lesions, invasive ovarian lesions and omental metastasis (68). In addition to identifying N-methyltransferase (NNMT) as a metabolic regulator of cancer associated fibroblasts, they also showed that the molecular profiles of primary cancers and metastatic implants were remarkably similar within the same patient while the microenvironment showed site specific differences. The STIC lesion they investigated showed lower expression compared to normal tube in 4 of our proteins of interest (CAPS, ERO1A, TPPP3, and SPATA18) and similar expression in 2 (EPCAM and SORD). Only VCAN showed marginally increased expression in STIC compared to normal fallopian tube epithelium in this analysis. The authors’ focus on stromal tissue, a lack of normal epithelial ovarian or omental controls and the potential that STIC represents metastatic lesions from a primary ovarian tumor limits further comparison to this data set.

The traditional understanding of cancer development is that it acquires metastatic capacities over time within the primary lesion (69). However, the identification of STIC as the origin site of HGSOC implicates that these pre-invasive lesions can leave their site of origin and establish themselves in distant locations. In addition, EIC is often identified with extraterine spread (18, 19) which can take the form of EIC like growths on the ovaries, peritoneum and fallopian tube in the absence of obvious disease in these locations (16, 18). Together, this suggests that these premalignant lesions possess some migratory or metastatic ability facilitating their translocation to distant sites within the gynecological system. Here, we identified numerous metastasis and migration related proteins in precancerous lesions in the absence of malignant disease (Supplementary Table 2).
A major limitation of this study is that the data is derived from a single patient case study which makes generalized interpretation of biological implication of this data difficult. Furthermore, only a modest number of proteins was identified from these small tissue regions. As highly abundant proteins are identified preferentially in mass spectrometry analysis (70), the low number of proteins identified potentially masks differences in lower abundance proteins. The analysis of a larger cohort, coupled with the utilization of advanced sample preparation and mass spectrometry techniques to improve proteome coverage, holds the potential to build upon the data presented here and paint a clearer picture of the molecular landscape of precancerous lesions of serous cancers of the ovary and endometrium.

CONCLUSION

Here, we present the first proteomic investigation of precancerous lesions of the gynecological tract in a patient without advanced gynecological malignancy. Interpretation of the data is limited by the single case study and the modest number of proteins identified; however, we provide a foundation for further analysis of the molecular links between precancerous lesions and subsequent cancer. In addition, we identified several metastasis-related proteins in precancerous tissues. The understanding that precancerous lesions of the female genital tract potentially possess metastatic potential raises many questions about when, where, and how these cancers develop. Though the early steps are not well understood, further proteomic analyses of gynecological precancerous lesions hold the potential to unravel the early temporal and molecular events underlying the development of these malignancies which, in turn, holds the potential to improve detection and treatment.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. These can be found in the NCBI Gene Expression Omnibus. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (71) with the data set identifier PXD018538.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Research Ethics Committee of the Royal Adelaide Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

Design of the work: MO, PH, GA, and MA. Acquisition, analysis, and interpretation of data: all authors. Drafting the work or revising it critically: all authors. All authors contributed to the article and approved the submitted version.

FUNDING

PH gratefully acknowledges the support of the National Collaborative Research Infrastructure Strategy (NCRIS) Bioplatforms Australia Node for Tissue Imaging Mass Spectrometry.

ACKNOWLEDGMENTS

We acknowledge the contribution of Lyron Winderbaum in analyzing the preliminary proteomics and genomics data gathered.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.523989/full#supplementary-material

REFERENCES

1. Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet (2015) 131(Suppl 2):S96–104. doi: 10.1016/j.ijgo.2015.06.005
2. Costas L, Frias-Gomez J, Guardiola M, Benavente Y, Pineda M, Pavon MA, et al. New perspectives on screening and early detection of endometrial cancer. Int J Cancer (2019) 145(12):3194–206. doi: 10.1002/ijc.32514
3. Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer (2019) 19(9):510–21. doi: 10.1038/s41560-019-0177-x
4. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature (2013) 497(7447):67–73. doi: 10.1038/nature12113
5. Charo LM, Plaxe SC. Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019. F1000Res (2019) 8. doi: 10.12688/f1000research.17408.1
6. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2015) 136(5):E359–86. doi: 10.1002/ijc.29210
7. Arnold M, Pandeya N, Byrnes G, Renahan PAG, Stevens GA, Ezzati PM, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol (2015) 16(3):36–46. doi: 10.1016/S1470-2045(14)71234-3
8. Solow RA, Bissonnette JP, Wilton A, Ferguson SE, Aleksandia KM, Duska LR, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol (2007) 31(7):979–87. doi: 10.1097/PAS.0b013e31802ee494
9. Kelly MG, O’Malley D, Hui P, McAlpine J, Dzija J, Rutherford TJ, et al. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol (2004) 95(3):469–73. doi: 10.1016/j.ygyno.2004.08.030
10. Olawoye AB, Rauh-Hain JA, Witham-Leitch M, Rueda B, Goodman A, Del Carmen MG. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol (2008) 110(3):293–8. doi: 10.1016/j.ygyno.2008.05.027
11. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometroid corpus cancers. Br J Cancer (2006) 94:642–6. doi: 10.1038/sj.bjc.6603012

12. Zheng W, Liang SX, Yu H, Rutherford T, Chambers SK, Schwartz PE. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol (2004) 12(3):207–23. doi: 10.1071/PS0316318227722

13. Liang SX, Chambers SK, Cheng L, Zhang S, Zhou Y, Zheng W. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol (2004) 12(4):319–31. doi: 10.1071/PS04164200404

14. Zheng W, Xiang L, Fadare O, Kong B. A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol (2011) 35(1):e1–14. doi: 10.1097/PAS.0b013e3182277e

15. Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res (2008) 14(8):2263–9. doi: 10.1158/1078-0432.CCR-07-4837

16. Sherman ME, Bitterman P, Rosenhsien NB, Belardo G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol (1992) 16(6):600–10. doi: 10.1097/00000478-199206000-00008

17. Shermer ME, Belardo G, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol (1995) 26(11):1268–74. doi: 10.1006/1046-8177(95)90204-X

18. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol (2000) 24(6):797–806. doi: 10.1097/00000478-200006000-00004

19. Hui P, Kelly M, O’Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol (2005) 18(1):75–82. doi: 10.1038/modpathol.3800271

20. Talcher MC, Swisher EM, Medeiros F, Lima JF, Hilderbrand JL, Donovan JL, et al. Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma. Int J Gynecol Pathol (2013) 34(1):57–64. doi: 10.1007/10194720001009

21. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol (2010) 22(1):21–9. doi: 10.1097/GCO.0b013e32833d4b3a

22. Sovak MA, Hensley ML, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, et al. Andromeda: a peptide search engine integrated into the MaxQuant proteomics experimental results. Nat Methods (2011) 10(4):1794–805. doi: 10.1038/20101006

23. Mittal P, Klinger-Hoffmann M, Arentz G, Winderbaum L, Kaur G, Anderson L, et al. Annexin A2 and alpha actinin 4 expression correlates with metastatic potential of primary endometrial cancer. Biochim Biophys Acta Proteom Proteom (2017) 1865(7):846–57. doi: 10.1016/j.bbapap.2016.10.010

24. Wisniewski JR, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods (2009) 6(5):359–62. doi: 10.1038/nmeth.1322

25. Cox J, Neuhausser N, Michalski A, Scheltema RA, Olsen JV, Mann M. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res (2011) 10(4):1794–805. doi: 10.1021/pr101065c

26. Yoshinara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujisawa H, et al. Expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclass and implicates ZEB2 in tumor progression and prognosis. Cancer Sci (2009) 100(8):1421–8. doi: 10.1111/j.1349-7005.2009.01204.x

27. Hendrix ND, Wu R, Kuck R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenoacarcinomas. Cancer Res (2006) 66(3):1354–62. doi: 10.1158/0008-5472.CAN-05-3694

28. Day RS, McDade KK, Chandran UR, Lisovich A, Conrads TP, Hood BL, et al. Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinf (2011) 12:213. doi: 10.1186/1471-2105-12-213

29. Li Z, Huang C, Bai S, Pan X, Zhou R, Wei Y, et al. Prognostic evaluation of epithelial fatty acid-binding protein and calpoxin, two proteins implicated in endometrial cancer, using a proteomic approach. Int J Cancer (2018) 120(10):2377–83. doi: 10.1002/ijc.33808

30. Lai T, Sun H, Pan X, Huang Q, Wang H, Lee OK, et al. The role of EpCAM in tumor progression and the clinical prognosis of endometrial
carcinoma. Gynecol Oncol (2018) 148(2):383–92. doi: 10.1016/j.gyno. 2017.11.033

49. Tayama S, Motohara T, Narantuya D, Li C, Fujimoto K, Sakaguchi I, et al. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. Oncotarget (2017) 8 (27):44312–25. doi: 10.18632/oncotarget.17871

50. Erickson BK, Conner MG, Landen CN Jr. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 209(5):409–14. doi: 10.1016/j.ajog.2013.04.019

51. Blaustein A. Peritoneal mesothelium and ovarian surface cells–human cell lines. In: Bologna M, editor. Bioreactors of Cancer in Current Clinical Practice. Current Clinical Pathology. Humana Press (2012). p. 221–44. doi: 10.1007/978-1-61779-615-9_8

52. Sotzek PP, Chang HL, Brennand K, Fujino A, Pieretti-Vanmarcke R, Lo Celso C, et al. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci USA (2008) 105(34):12469–73. doi: 10.1073/pnas.0805012105

53. Fujihara S, Morii H, Kobarah H, Rafi K, Niki T, Hirashima M, et al. Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discovery (2013) 7 (2):130–7. doi: 10.2174/1872214811307020006

54. Cui X, Song B, Hou L, Wei Z, Tang J. High expression of osteoglycin decreases the metastatic capability of mouse hepatocarcinoma Hca-F cells to lymph nodes. Acta Biochim Biophys Sin (Shanghai) (2008) 40(4):349–55. doi: 10.1111/j.1745-7270.2008.00392.x

55. Wang L, Zhang F, Cui JY, Chen L, Chen YT, Liu BW. CAFs enhance paclitaxel resistance by inducing EMT through the IL6/JAK2/STAT3 pathway. Biochem Biophys Res Commun (2019) 471(1):130–9. doi: 10.1016/j.bbrc.2017.04.035

56. Lu TY, Lu RM, Liao MY, Yu J, Chung CH, Kao CF, et al. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Cell Res (2008) 18(3):513–20. doi: 10.1038/cr.2008.50

57. Beavon IR. E-cadherin–catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer (2000) 36(13 Spec No):1607–20. doi: 10.1016/S0959-8490(00)00158-1

58. Kobel M, Kalloger S, Boyd NJP. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5 (12):e232. doi: 10.1371/journal.pmed.0050232

59. Kusumoto T, Kodama I, Seki N, Nakamura K, Hongo A, Hiramatsu Y. Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep (2010) 23(4):917–25. doi: 10.3892/or_0000715

60. Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol (2011) 225(2):189–94. doi: 10.1002/path.2940

61. Kuechlin S, Schoels M, Slanchev K, Lassmann S, Walz G, Yakulov TA. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium. Glycobiology (2008) 18(9):735–44. doi: 10.1093/glycobi/osn062

62. Kusumoto T, Kodama I, Seki N, Nakamura K, Hongo A, Hiramatsu Y. Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep (2010) 23(4):917–25. doi: 10.3892/or_0000715

63. Clement S, Dumont JE, Schurmans S. Loss of calpain gene expression in mouse and other rodents. Biochem Biophys Res Commun (1997) 232(2):407–13. doi: 10.1006/bbrc.1997.6297

64. Cui X, Song B, Hou L, Wei Z, Tang J. High expression of osteoglycin decreases the metastatic capability of mouse hepatocarcinoma Hca-F cells to lymph nodes. Acta Biochim Biophys Sin (Shanghai) (2008) 40(4):349–55. doi: 10.1111/j.1745-7270.2008.00392.x

65. Nakagawa H, Kiyohara S, Kubota M, Yoneyama H, Hotta A. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 209(5):409–14. doi: 10.1016/j.ajog.2013.04.019

Conflict of Interest: Author FW was employed by the company Clínpath. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Acland, Arentz, Massareu, Whitehead, Hoffmann, Klenger-Hoffmann and Oehler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.